Cited by 218Barrier Structure and Function StudiesAngiogenesis and VEGF in CancerNeurological Disorders and Treatments

The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia

Kilic, Ertugrul, Kilic, Ülkan, Wang, Yaoming, Bassetti, Claudio L., Marti, Hugo H., Hermann, Dirk M., Kilic, Ertugrul, Kilic, Ülkan +4 more·2006·The FASEB Journal

Abstract

Based on its trophic influence on neurons and vascular cells, vascular endothelial growth factor (VEGF) is a promising candidate for stroke treatment. VEGF's survival-promoting effects are purchased at the expense of an increased blood brain barrier permeability, which potentially compromises tissue survival. The mechanisms via which VEGF protects the brain against ischemia remained unknown. We examined signaling pathways underlying VEGF's neuroprotective activity in our transgenic mouse line, which expresses human VEGF165 under a neuron-specific enolase (NSE) promoter. We show that VEGF receptor-2 (Flk-1) is expressed on ischemic neurons and astrocytes and is activated by VEGF. Following 90-min episodes of middle cerebral artery occlusion, VEGF increased phosphorylated (but not total) Akt and ERK-1/-2 and reduced phosphorylated mitogen activated protein kinase/p38 and c-Jun NH2-terminal kinase (JNK)-1/-2 levels, at the same time decreasing inducible NO synthase expression in ischemic neurons. Inhibition of Akt with Wortmannin reversed VEGF's neuroprotective properties, diminished brain swelling, and restored the vascular permeability induced by VEGF to below levels in WT animals. The aggravation of brain injury by Wortmannin was associated with the restitution of p38, but not of JNK-1/-2, ERK-1/-2, or inducible NOS (iNOS). Our data demonstrate that VEGF mediates both neuroprotection and blood brain barrier permeability via the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Based on our observation that VEGF neuroprotection and vascular leakage depend on PI3K/Akt, which is putatively regulated by VEGF receptor-2, we predict that it may not easily be possible to make use of VEGF's neuroprotective function without accepting its unfavorable consequence, the increased vascular permeability.

Integrity signals

Registry

Crossref · 10.1096/fj.05-4829fje

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kilic, E., Kilic, Ü., Wang, Y., Bassetti, C. L., Marti, H. H., Hermann, D. M., Kilic, E., Kilic, Ü., Wang, Y., Bassetti, C. L., Marti, H. H., & Hermann, D. M.
Venue
The FASEB Journal
Publisher
Wiley
Published
2006-04-26
Volume
20
Issue
8
Pages
1185-1187
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2153508530
Cited by
218
References
26
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 14 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 4 · 2017: 12 · 2016: 12 · 2015: 13 · 2014: 16 · 2013: 11 · 2012: 17
FWCI
12.50
Type
journal article
Language
en
Open access
closed
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Stiftung für die Erforschung der Muskelkrankheiten (3200B0-100790)
  • nccr – on the move
  • Hartmann Müller-Stiftung für Medizinische Forschung
  • Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
  • Baden-Württemberg Stiftung (23-7532.22-2012/1)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
vascular endothelial growth factor, VEGF receptor 2, Flk-1, PI3K/Akt signaling, neuroprotection, blood-brain barrier permeability, focal cerebral ischemia, stroke, p38 MAPK, JNK, ERK, inducible nitric oxide synthase, wortmannin, middle cerebral artery occlusion, cerebral edema
MeSH terms
Wortmannin, Phosphoinositide-3 Kinase Inhibitors, Androstadienes, Animals, Astrocytes, Blood-Brain Barrier, Capillary Permeability, Brain Ischemia, Enzyme Inhibitors, Humans, Mice, Transgenic, Neurons, Signal Transduction, Neuroprotective Agents, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Proto-Oncogene Proteins c-akt, Mice, Nitric Oxide Synthase Type II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review